Celgene falls 8 percent after Wellington Management says it opposes Bristol-Myers acquisition

In January, Bristol-Myers Squibb announced its plans to buy cancer drugmaker Celgene in a c ash and stock deal valued at $74 billion. Wellington said in a release that it "does not believe that the Celgene transaction is an attractive path towards" business that "secures differentiated science and broadens the future revenue base." Wellington said the...